Background Twelve percent of all acute liver failure (ALF) cases are of unknown origin, often
termed indeterminate. A previously unrecognized hepatotropic virus has been suspected as …

Hepatitis C virus (HCV) exploits the four entry factors CD81, scavenger receptor class B type
I (SR-BI, also known as SCARB1), occludin, and claudin-1 as well as the co-factor epidermal …

An estimated 170 million people, approximately 3% of the world population, are chronically
infected with the hepatitis C virus (HCV). More than 350 000 deaths are reported annually …

The presented study had two objectives. The first was to examine distributions of Hepatitis C
Virus (HCV) genotypes in Sindh, Pakistan, where HCV is prevalent. The other was to …

Hepatitis C virus (HCV) is an important causative agent of acute and chronic hepatitis. The
non-structural protein 3 (NS3) of HCV retains two enzymatic domains which are essential for …

Background The HCV NS3/4A serine protease inhibitors (PIs) boceprevir (BOC), telaprevir
(TVR) and simeprevir (SMV) are approved for treatment of chronic hepatitis C infection in …

Background Blood donors are, in principle, healthy individuals who may be revealed as
infectious for blood‐borne agents by the laboratory screening process, depicting the …

Background In low‐risk populations, variability in the sensitivity of current serological tests
for Hepatitis C virus (HCV) blood donor screening may lead to the presence of false‐positive …

BACKGROUND Hepatitis C virus genotype 3a (HCV G3a) is highly prevalent in Pakistan.
Due to the elevated cost of available Food and Drug Administration-approved drugs against …

Background HCV treatment options and cure rates have tremendously increased in the last
decade. Although a pan-genotype HCV treatment has recently been approved, most DAA …